83-2270-50　［受注停止］KRIBIOLISA Alemtuzumab （LEMTRADA） ELISA 1 x 96 wells　KBI1012

特徴

• Description：Enzyme Immunoassay for the quantitative determination of Alemtuzumab in serum, plasma and cell culture supernatant
• .
• Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia （CLL）, cutaneous T-cell lymphoma （CTCL） and T-cell lymphoma under the trade names Campath, MabCampath and Campath-1H, and in the treatment of multiple sclerosis as Lemtrada.
• It is also used in some conditioning regimens for bone marrow transplantation, kidney transplantation and islet cell transplantation.
• It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived.
• After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.
• MabCampath was withdrawn from the markets in the US and Europe in 2012 to prepare for a higher-priced relaunch of Lemtrada aimed at multiple sclerosis.
• Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The method employs the quantitative sandwich enzyme immunoassay technique.
• Antibodies to Alemtuzumab are pre-coated onto microwells.
• Samples and standards are pipetted into microwells and human Alemtuzumab present in the sample are bound by the capture antibody.
• Then, a HRP （horseradish peroxidase） conjugated anti-Alemtuzumab antibody is pipetted and incubated.
• After washing microwells in order to remove any non-specific binding, the ready to use substrate solution （TMB） is added to microwells
• and color develops proportionally to the amount of Alemtuzumab in the sample.
• Color development is then stopped by addition of stop solution.
• Absorbance is measured at 450 nm.